Anhui and Jiangsu provinces announced that another 53 batches of drugs did not meet the requirements
Release date: 2019-12-27 Views: 0
Source: Anhui Drug Administration, Jiangsu Drug Administration
The two provinces noticed that another 53 batches of drugs did not meet the requirements. The drug supervisor required investigation and punishment according to law, involving amlodipine maleate tablets, Ningxinbao capsules, triamcinolone nasal spray, Jiuweihaohuo pills, anti-inflammatory and choleretic Tablets, Zheng Chai Hu Yin granules ...
Anhui: 12 batches of drugs investigated
On December 24, the Anhui Provincial Drug Administration issued the fourth issue of drug quality announcement for 2019. According to the announcement, according to the Anhui Province's drug sampling and inspection plan, the market supervision and management departments and drug inspection agencies at all levels throughout the province have conducted supervision and sampling on the drug quality of pharmaceutical production, operation enterprises and users in their respective administrative regions.
标准 规定，不符合规定项目包括【性状】、【检查】装量差异、总灰分、水分、黄曲霉毒素、微生物限度、【含量测定】。 The announcement pointed out that after random inspection and verification, a total of 11 varieties and 12 batches of drugs did not meet the standard requirements, and the non-compliant items included [character], [inspection] loading differences, total ash, moisture, aflatoxin, microbial limits, [Content determination]. For the drugs and related units that do not meet the requirements of the above-mentioned sampling tests, the market supervision and management departments at all levels are investigating and punishing them according to law.
Jiangsu: Investigation and punishment of 41 batches of drugs
On December 23, the Jiangsu Provincial Drug Administration issued a notice on the quality of medicines for the third period of 2019. According to the notice, in accordance with the Jiangsu Province Drug Administration's annual sampling inspection work plan, the bureau organized a random inspection of drug production, operation and use units. The 41 batches of non-compliance drugs found by random inspection are now notified.
The bureau pointed out that for drugs that do not meet the requirements, the drug supervision and administration departments at all levels in our province have required relevant enterprises and units to investigate and implement rectification of the reasons for non-compliance based on risk control measures such as suspension of sales and use. The drug supervision and administration departments at all levels in our province have organized investigations and punishments against relevant enterprises and units in accordance with the law.
- Basic introduction of Heilongjiang Hexiang Pharmaceutical Co., Ltd.
- How to contact Bermuda (Shanghai) Regenerative Medicine Technology Co., Ltd.
- Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Brief introduction of Zaozhuang Yinhai Pharmaceutical Co., Ltd.
- Contact information of Shandong Dongfang Huiyi Health Industry Co., Ltd.
- Brief introduction of Bermudi (Shanghai) Regenerative Medicine Technology Co., Ltd.
- GSK、豪森、恒瑞、信立泰等药企未中选品种主动降价 1. GSK, Haosen, Hengrui, Xinlitai and other pharmaceutical companies have not actively selected prices to reduce prices
- 25省扩围“4+7” 中选企业全分析 2. Full analysis of selected enterprises in the “4 + 7” expansion in 25 provinces
- 2019药企“十大”典型罚单最高8317万 3. The top ten typical fines for pharmaceutical companies in 2019 are 83.17 million
- 三省年底大抽查！ 4. Big spot check at the end of the three provinces! A large number of commonly used drugs were investigated, involving dozens of pharmaceutical companies, all of which were inferior drugs!
- 安徽、江苏省通告，又有53批次药不符合规定 5.Announcements from Anhui and Jiangsu Province, 53 batches of drugs do not meet the requirements
- 卫健委发文连续3年全国考核5类药使用 6. The health and health committee issued a document to assess the use of 5 types of drugs for 3 consecutive years
- 石锤！ 7. Stone Hammer! Two drug companies sell inferior drugs, fine!